Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently amended) A compound of formula



(I),

or a stereoisomer or ~~including the stereoisomers and the~~ pharmaceutically acceptable ~~addition salts~~ salt thereof,

wherein:

R^1 is NR^4R^5 ~~or OR^5~~;

R^2 is C_{1-6}alkyl~~; C_{1-6}alkyloxy or C_{1-6}alkylthio~~;

R^3 is hydrogen, C_{1-6}alkyl, C_{1-6}alkylsulfonyl, ~~C_{1-6}alkylsulfoxy~~ or C_{1-6}alkylthio;

R^4 is hydrogen~~;~~ or C_{1-6}alkyl~~, mono- or di(C_{3-6}cycloalkyl)methyl, C_{3-6}cycloalkyl, C_{3-6}alkenyl, hydroxyC_{1-6}alkyl, C_{1-6}alkylcarbonyloxyC_{1-6}alkyl or C_{1-6}alkyloxyC_{1-6}alkyl~~;

R^5 is C_{1-8}alkyl, ~~mono- or di(C_{3-6}alkylcycloalkyl)methyl, Ar^+CH_2; C_{3-6}alkenyl;~~ C_{1-6}alkyloxyC_{1-6}alkyl~~;~~ or hydroxyC_{1-6}alkyl, ~~thienylmethyl, furanylmethyl, C_{1-6}alkylthioC_{1-6}alkyl, morpholinyl, mono- or di(C_{1-6}alkyl)aminoC_{1-6}alkyl, di(C_{1-6}alkyl)amino, C_{1-6}alkylcarbonylC_{1-6}alkyl, C_{1-6}alkyl substituted with imidazolyl; or a radical of formula -Alk-O-CO-Ar^+~~;

~~or R^4 and R^5 taken together with the nitrogen atom to which they are attached may form a pyrrolidinyl, piperidinyl, homopiperidinyl or morpholinyl group, optionally substituted with C_{1-6}alkyl or C_{1-6}alkyloxyC_{1-6}alkyl;~~ and

Ar is phenyl; phenyl substituted with 1, 2 or 3 substituents independently selected from halo, C_{1-6}alkyl, ~~trifluoromethyl, hydroxy, cyano,~~ C_{1-6}alkyloxy, ~~benzyloxy, C_{1-6}alkylthio, nitro,~~ amino and mono- and di(C_{1-6}alkyl)amino; pyridinyl; pyridinyl substituted with 1, 2 or 3 substituents independently selected from halo, C_{1-6}alkyl, ~~trifluoromethyl, hydroxy, cyano,~~ C_{1-6}alkyloxy, ~~benzyloxy, C_{1-6}alkylthio, nitro,~~ amino, and mono- or di(C_{1-6}alkyl)amino ~~and piperidinyl~~; and wherein said substituted phenyl may optionally be further substituted with one or more halogens;

~~Ar^+ is phenyl; phenyl substituted with 1, 2 or 3 substituents each independently selected from halo, C_{1-6}alkyl, C_{1-6}alkyloxy, di(C_{1-6}alkyl)aminoC_{1-6}alkyl, trifluoromethyl and C_{1-6}alkyl substituted with morpholinyl; or pyridinyl; and~~

~~Alk is C_{1-6}alkanediyl;~~

with the proviso that ~~5-methyl-3-phenyl-7-(phenylmethoxy)-pyrazolo[1,5-a]-pyrimidine and~~ 2,5-dimethyl-7-(methylamino)-3-phenyl-pyrazolo[1,5-a]pyrimidine ~~are~~ is not included.

2-13. (Cancelled)

14. (New) A compound according to claim 1, wherein R^3 is hydrogen, C_{1-6}alkyl or C_{1-6}alkylthio.

15. (New) A compound according to claim 14, wherein R^3 is hydrogen, methyl or CH_3S-.

16. (New) A compound according to claim 1, wherein R^4 is hydrogen or C_{2-4}alkyl.

17. (New) A compound according to claim 16, wherein R^4 is hydrogen or n-propyl.

18. (New) A compound according to claim 1, wherein Ar is phenyl substituted with 1, 2 or 3 substituents independently selected from halo and C_{1-6}alkyloxy; or Ar is pyridinyl substituted with 1, 2 or 3 substituents independently selected from halo, C_{1-6}alkyl and di(C_{1-6}alkyl)amino.

19. (New) A compound according to claim 18, wherein Ar is phenyl substituted with 2 or 3 substituents independently selected from halo and methoxy; or Ar is pyridinyl substituted with 2 or 3 substituents independently selected from halo, methyl and dimethylamino.

20. (New) A compound according to claim 1, wherein R^2 is methyl.

21. (New) A compound according to claim 1, wherein R^3 is hydrogen, C_{1-6}alkyl or C_{1-6}alkylthio; R^4 is hydrogen or C_{2-4}alkyl; and Ar is phenyl substituted with 1, 2 or 3 substituents independently selected from halo and C_{1-6}alkyloxy, or pyridinyl substituted with 1, 2 or 3 substituents independently selected from halo, C_{1-6}alkyl and di(C_{1-6}alkyl)amino.

22. (New) A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a therapeutically effective amount of a compound according to claim 1.

23. (New) A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a therapeutically effective amount of a compound according to claim 15.

24. (New) A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a therapeutically effective amount of a compound according to claim 17.

25. (New) A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a therapeutically effective amount of a compound according to claim 19.

26. (New) A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a therapeutically effective amount of a compound according to claim 21.

27. (New) A method for treating an endocrine, psychiatric or neurologic disorder or illness in a warm-blooded animal comprising administering to said animal in need of treatment a therapeutically effective amount of a compound according to claim 1.

28. (New) A method for treating an endocrine, psychiatric or neurologic disorder or illness in a warm-blooded animal comprising administering to said animal in need of treatment a therapeutically effective amount of a compound according to claim 18.

29. (New) A method for treating an endocrine, psychiatric or neurologic disorder or illness in a warm-blooded animal comprising administering to an animal in need thereof a therapeutically effective amount of a compound according to claim 21.

30. (New) A method for treating a physiological condition or disorder in a warm-blooded animal arising from the hyper-secretion of corticotrophin-releasing

factor comprising administering to an animal in need thereof a therapeutically effective amount of a compound according to claim 1.

31. (New) A method for treating a physiological condition or disorder in a warm-blooded animal arising from the hyper-secretion of corticotrophin-releasing factor comprising administering to an animal in need thereof a therapeutically effective amount of a compound according to claim 18.

32. (New) A method for treating a physiological condition or disorder in a warm-blooded animal arising from the hyper-secretion of corticotrophin-releasing factor comprising administering to an animal in need thereof a therapeutically effective amount of a compound according to claim 21.